多发性骨髓瘤的流行病学全景:全球癌症登记对疾病负担、危险因素和时间趋势的估计
该研究从全球癌症观察站(2020)、五大洲癌症发病率、WHO死亡数据库、北欧癌症登记和美国SEER(1980-2019)提取多发性骨髓瘤发病与死亡数据,用多变量回归分析危险因素、joinpoint回归计算平均年度百分比变化。2020年全球年龄标化发病率为1.78/10万、死亡率为1.14/10万;发病率与人类发展指数、GDP、缺乏运动、超重、肥胖和糖尿病患病率升高相关;全球发病率总体呈上升趋势,死亡率总体呈下降趋势。
要点
- 2020年全球多发性骨髓瘤年龄标化发病率为1.78/10万(95% UI 1.69-1.87),死亡率为1.14/10万(95% UI 1.07-1.21)。
- 发病率最高的地区为澳大利亚与新西兰(4.86)、北美(4.74)和北欧(3.82);最低为西非(0.81)、美拉尼西亚(0.87)和东南亚(0.96)。
- 全球发病率总体呈上升趋势,50岁及以上男性增幅最大的国家为德国(AAPC 6.71)、丹麦(3.93)和韩国(3.25);全球死亡率总体呈下降趋势。
核心结论
- 全球多发性骨髓瘤发病率呈上升趋势,尤其在男性、50岁及以上人群和高收入国家人群中更为明显;全球死亡率总体下降趋势在女性中更明显。
- 作者认为应改善生活习惯、诊断能力和治疗可及性以控制高危人群多发性骨髓瘤的上升趋势,未来研究应探索这些流行病学转变背后的原因。
研究设计与样本
- 研究从全球癌症观察站(2020)、五大洲癌症发病率、WHO死亡数据库、北欧癌症登记和美国SEER项目(1980-2019)提取多发性骨髓瘤发病与死亡数据。
- 从WHO全球卫生观察站数据仓库检索生活方式和代谢危险因素的年龄标化患病率(2010),用多变量回归分析危险因素关联,用joinpoint回归计算平均年度百分比变化(AAPC)评估时间趋势。
主要发现
- 2020年全球多发性骨髓瘤年龄标化发病率为1.78/10万(95% UI 1.69-1.87),死亡率为1.14/10万(95% UI 1.07-1.21)。
- 发病率升高与人类发展指数、国内生产总值、缺乏运动、超重、肥胖和糖尿病患病率升高相关。
- 发病率最高地区为澳大利亚与新西兰(4.86 [4.66-5.07])、北美(4.74 [4.69-4.79])和北欧(3.82 [3.71-3.93]);最低为西非(0.81 [0.39-1.66])、美拉尼西亚(0.87 [0.55-1.37])和东南亚(0.96 [0.73-1.27])。
- 50岁及以上男性发病率增幅最大的国家为德国(AAPC 6.71 [95% CI 0.75-13.02] p=0.027)、丹麦(3.93 [2.44-5.45] p=0.00027)和韩国(3.25 [0.69-5.88] p=0.019);50岁及以上女性增幅最大为法罗群岛(21.01 [2.15-43.34] p=0.032)、丹麦(4.70 [1.68-7.82] p=0.0068)和以色列(2.57 [0.74-4.43] p=0.012)。
- 死亡率最高地区为波利尼西亚(2.69 [0.74-9.81])、澳大利亚与新西兰(1.84 [1.73-1.96])和北欧(1.80 [1.73-1.88]);最低为东南亚(0.82 [0.62-1.09])、东亚(0.76 [0.71-0.81])和美拉尼西亚(0.73 [0.61-0.87]);男性死亡率(1.41 [1.29-1.53])高于女性(0.93 [0.85-1.02])。
临床怎么用
- 作者认为应改善生活习惯、诊断能力和治疗可及性,以控制高危人群多发性骨髓瘤的上升趋势。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple myeloma accounted for 176 404 (14%) of 1 278 362 the incidence cases leukaemia, lymphoma, and multiple myeloma in 2020. Identifying its geographical distribution, risk factors, and epidemiological trends could help identify high-risk population groups. We aimed to examine the worldwide incidence, mortality, associated risk factors, and temporal trends of multiple myeloma by sex, age, and geographical region. METHODS: The incidence and mortality of multiple myeloma were extracted from Global Cancer Observatory (2020), Cancer Incidence in Five Continents, WHO mortality database, Nordic Cancer Registries, and Surveillance, Epidemiology, and End Results Program (1980-2019). The WHO Global Health Observatory data repository was searched for the age-standardised prevalence of lifestyle and metabolic risk factors (2010). Associations with risk factors were examined by multivariable regression. The temporal trends were evaluated by average annual percentage change (AAPC) using joinpoint regression. FINDINGS: The age-standardised rate (ASR) of multiple myeloma incidence was 1·78 (95% UI 1·69-1·87) per 100 000 people globally and mortality was 1·14 (95% UI 1·07-1·21) per 100 000 people globally in 2020. Increased incidence and mortality were associated with higher human development index, gross domestics product, prevalence of physical inactivity, overweight, obesity, and diabetes. Australia and New Zealand (ASR 4·86 [4·66-5·07]), northern America (4·74 [4·69-4·79]), and northern Europe (3·82 [3·71-3·93]) reported the highest incidence. The lowest incidences were observed in western Africa (0·81 [0·39-1·66]), Melanesia (0·87 [0·55-1·37]), and southeastern Asia (0·96 [0·73-1·27]). Overall, more countries had an increase in incidence, especially in men aged 50 years or older. The countries with the highest incidence increase in men older than 50 years were Germany (AAPC 6·71 [95% CI 0·75-13·02] p=0·027), Denmark (3·93 [2·44-5·45] p=0·00027), and South Korea (3·25 [0·69-5·88] p=0·019). For women aged 50 years or older, Faroe Islands (21·01 [2·15-43·34] p=0·032), Denmark (4·70 [1·68-7·82], p=0·0068), and Israel (2·57 [0·74-4·43] p=0·012) reported the greatest increases. Overall, there was a decreasing trend for multiple myeloma mortality. The highest mortality was observed in Polynesia (ASR 2·69 [0·74-9·81]), followed by Australia and New Zealand (1·84 [1·73-1·96]) and northern Europe (1·80 [1·73-1·88]). The lowest mortalities were reported in southeastern Asia (ASR 0·82 [0·62-1·09]), eastern Asia (0·76 [0·71-0·81]), and Melanesia (0·73 [0·61-0·87]). Men (1·41 [1·29-1·53]) were found to have mortality higher than women (0·93 [0·85-1·02]). INTERPRETATION: There was an increasing trend of multiple myeloma incidence globally, particularly in men, people aged 50 years or older, and those from high-income countries. The overall decreasing global trend of multiple myeloma mortality was more evident in women. Lifestyle habits, diagnosis capacity, and treatment availability should be improved to control the increasing trends of multiple myeloma in high-risk populations. Future studies should explore the reasons behind these epidemiological transitions. FUNDING: None.
引用
- Huang J, Chan SC, Lok V, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol. 2022. PMID: 35843248. doi:10.1016/S2352-3026(22)00165-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。